Aolu Pharmaceuticals completes 100 million US dollars Series A financing.

On December 5th, Shanghai Aouru Biopharmaceutical Technology Co., Ltd. announced that it has successfully completed a $100 million Series A funding round in June 2025. This round of funding was led by Temasek's wholly-owned subsidiary Tamim Capital, Lilly Asia Ventures, Pfizer Ventures, and Sirona Capital.